Thus, comparison of the M0 and M1 co-injected tumors clearly demonstrated that treatment with M1 inhibits tumor growth and changes composition of the myeloid and lymphoid intratumoral cell subsets by inhibiting infiltration of CD11b+ cells, increasing proinflammatory iNOs+ phenotype of the myeloid cells, and decreasing the number of T-regs in the TME. The gene discussed is NOS2; the disease is neoplasm.